Powered by our Glyph platform we are advancing first and best-in-class medicines for people living with neuropsychiatric disorders.

Powered by our Glyph platform we are advancing first and best-in-class medicines for people living with neuropsychiatric disorders.

We have a proven strategy of advancing clinically validated mechanisms — previously held back by limitations — which our technology platform can now overcome.

OUR PROGRAMS1

GLYPH™ BENEFIT

DISCOVERY

PRECLINICAL

PHASE 1

PHASE 2

SPT-300

Glyph Allopregnanolone

GLYPH™ BENEFIT

Overcome lack of oral bioavailability

Major depressive disorder (MDD) with anxious distress
Major depressive disorder (MDD) with anxious distress
PHASE: 2

SPT-320

Glyph Agomelatine

GLYPH™ BENEFIT

Negate need for liver function testing

Generalized anxiety disorder, MDD
Generalized anxiety disorder, MDD
PHASE: PRECLINICAL

SPT-348

Non-hallucinogenic neuroplastogen

GLYPH™ BENEFIT

Improve PK & tolerability

Mood & neuropsychiatric disorders
Mood & neuropsychiatric disorders
PHASE: DISCOVERY

Completed

In-progress

Multiple discovery/preclinical programs underway leveraging the Glyph™ platform

1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our therapeutic candidates are safe and effective.
No regulatory agency has made any such determination that our therapeutics are safe or effective for use by the general public for any indication.

Proprietary platform advances active drugs previously limited by low oral bioavailablity/hepatotoxicity.

Glyph™ is based on the pioneering research of the Porter research group at Monash University in Melbourne.

Christopher Porter, Ph.D.

Original Co-inventor of Glyph Technology, Director of the Monash Institute of Pharmaceutical Sciences

The group and it’s collaborators have published research in multiple publications supporting the Glyph™ platform’s capabilities.

Co-inventors of the breakthrough technology include members of the Seaport and PureTech teams.

Jamie Simpson, Ph.D.

Original Co-inventor of Glyph Technology, Head of Chemistry at Seaport

Dan Bonner, Ph.D.

Co-founder, Senior Vice President, Platform at Seaport

KarXT, which was invented and developed by members of our team, has demonstrated notable improvements across schizophrenia symptoms – without the debilitating side effects of existing drugs – and is now poised to be the first new class of medicine in over 50 years for patients living with schizophrenia. KarXT was named the most anticipated drug launch of 2024 by Evaluate Vantage.

Karuna was acquired by Bristol Myers Squibb for $14B in March 2024.

Patient Need

Schizophrenia is a chronic psychiatric condition affecting 21M+ people globally. Up to 74% of patients discontinue medication before 18 months, with many failing to find an effective and/or tolerable therapy. Patients are in need of medicines that work differently than the current standards of care, which can cause weight gain, sedation and movement disorders.

Validated Efficacy

Xanomeline had generated exciting efficacy data at Eli Lilly, under the leadership of Steve Paul, but the drug was not advanced due to tolerability issues.

Our Team's Innovation:

To overcome this, KarXT was invented by combining xanomeline (a muscarinic receptor agonist) with trospium (a peripherally acting antagonist that doesn’t cross the blood brain barrier), and in doing so, our team unlocked development of the first new class of medicine for schizophrenia in over 50 years. This new medicine was invented at PureTech and advanced by Karuna, which was co-founded and led by members of our team.

Seaport Therapeutics
6 Tide Street
Seaport Boston, MA 02210

© 2024 Seaport Therapeutics